Human non-small cell lung cancer expresses putative cancer stem cell markers and exhibits the transcriptomic profile of multipotent cells

Norashikin Zakaria¹, Narazah Mohd Yusoff¹, Zubaidah Zakaria², Moon Nian Lim², Puteri J Noor Baharuddin², Kamal Shaik Fakiruddin² and Badrul Yahaya¹*

Abstract

Background: Despite significant advances in staging and therapies, lung cancer remains a major cause of cancer-related lethality due to its high incidence and recurrence. Clearly, a novel approach is required to develop new therapies to treat this devastating disease. Recent evidence indicates that tumours contain a small population of cells known as cancer stem cells (CSCs) that are responsible for tumour maintenance, spreading and resistant to chemotherapy. The genetic composition of CSCs so far is not fully understood, but manipulation of the specific genes that maintain their integrity would be beneficial for developing strategies to combat cancer. Therefore, the goal of this study is to identify the transcriptomic composition and biological functions of CSCs from non-small cell lung cancer (NSCLC).

Methods: We isolated putative lung CSCs from lung adenocarcinoma cells (A549 and H2170) and normal stem cells from normal bronchial epithelial cells (PHBEC) on the basis of positive expression of stem cell surface markers (CD166, CD44, and EpCAM) using fluorescence-activated cell sorting. The isolated cells were then characterised for their self-renewal characteristics, differentiation capabilities, expression of stem cell transcription factor and in vivo tumouregenicity. The transcriptomic profiles of putative lung CSCs then were obtained using microarray analysis. Significantly regulated genes (p < 0.05, fold change (FC) > 2.0) in putative CSCs were identified and further analysed for their biological functions using the Database for Annotation, Visualization, and Integrated Discovery (DAVID).

Results: The putative lung CSCs phenotypes of CD166+/CD44+ and CD166+/EpCAM+ showed multipotent characteristics of stem cells, including the ability to differentiate into adipogenic and osteogenic cells, self-renewal, and expression of stem cell transcription factors such as Sox2 and Oct3/4. Moreover, the cells also shows the in vivo tumouregenicity characteristic when transplanted into nude mice. Microarray and bioinformatics data analyses revealed that the putative lung CSCs have molecular signatures of both normal and cancer stem cells and that the most prominent biological functions are associated with angiogenesis, migration, pro-apoptosis and anti-apoptosis, osteoblast differentiation, mesenchymal cell differentiation, and mesenchyme development. Additionally, self-renewal pathways such as the Wnt and hedgehog signalling pathways, cancer pathways, and extracellular matrix (ECM)-receptor interaction pathways are significantly associated with the putative lung CSCs.

Conclusion: This study revealed that isolated lung CSCs exhibit the characteristics of multipotent stem cells and that their genetic composition might be valuable for future gene and stem cells therapy for lung cancer.

Keywords: Cancer stem cells, Non-small cell lung cancer, Cell surface marker, Transcriptome
Background
Lung cancer is one of the most common malignancies throughout the world. It accounted for about 16.1 million deaths in 2008 and is the leading cause of cancer-related death [1]. Based on pathological features, lung cancer is classified into two major groups; small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC). The majority of lung cancer cases are NSCLC (80%). NSCLC is less aggressive than SCLC. NSCLC tends to grow and spread slower than SCLC, which is fast growing and rapidly spreads to the bloodstream and other parts of the body. The three main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large-cell carcinoma. The prognosis for patients with NSCLC remains very poor, with only 15% survival within 5 years after treatment [2,3]. Moreover, the recurrence rate ranges from 35% to 50% among early stage NSCLC patients: After an apparently successful initial therapy, development of secondary tumours often leads to a lethal relapse.

The biological characteristics associated with the aggressive behaviour of cancer cells is driven by a subpopulation of cells within the tumour called cancer stem cells (CSCs) [4,5]. CSCs were first described in human hematopoietic cancer, and to date they have been identified in solid tumours of breast [6], pancreas [7], brain [8], and colon [9,10] cancers. CSCs can self-renew, initiate tumour development, and differentiate into multiple cell types [4,11-13], and recent evidence suggests that these cells play a central role in the progression of malignant tumours. The CSC model describes the existence of a small subpopulation of plastic cells with transdifferentiation potential in tumours. However, recent studies suggest that a major proportion of cells within tumours maintain stem cell properties and even more differentiated cells can be transformed into stem-like cells [13,14]. If this is the case, eradication of CSCs might not be a useful strategy for the reduction of tumour growth. Therefore, it is important to understand CSCs biology and identify new strategies to prevent malignant tumour progression. The mechanisms that regulate self-renewal of both CSCs and normal stem cells are thought to be similar [4].

Currently, identification and isolation of CSCs is largely dependent on the presence of specific cell surface markers [10,15], although the expression of such markers depends on various factors (e.g., the differentiation state of the cells and niche factors). Many of the markers used to identify CSCs are derived from the surface markers known to be present on normal hematopoietic or embryonic stem cells. CD133 has been used as a putative stem cell marker in glioblastoma [16] and colon cancer [9]; CD34 expressing tumour epithelial cells have been used as a marker in cutaneous cancer [17]; and CD44 expressing cells have been used as a marker in breast cancer [18]. Moreover, CD26 positive cells are indicative of metastases, invasiveness, and chemoresistance in colon cancer, and CD271 positive cells initiate melanoma progression and metastasis [19]. For lung CSCs, CD133 [20], CD166 [21], EpCAM, CD90, and CD44 [15,22] have been used as markers. CD133 is a well-described CSC marker in various types of cancers, including hematopoietic [23], brain [11], colon [10], pancreatic [7], and lung [20] cancers. In NSCLC and SCLC patient samples, CD133* cells possess tumourigenic and self-renewal characteristics [20]. However, several studies suggest that the use of CD133 expression to discriminate lung CSCs is overstated. For example, some CD133* lung cancer cells also possess the ability to self-renew and generate the formation of xenograft when transplanted into recipient mice [24]. Unlike in gliomas, where CD133 is a more established cancer stem cell marker, CD133 expression in lung cancer is not associated with patient prognosis [25-27]. Moreover, in many lung cancer samples, CD133 is not detected [26-28]. Recently, few scientists have questioned the use of CD133 as a selective CSCs marker in other solid tumour types, citing cases where CD133* cells also possess the capacity for self-renewal and cancer initiation [29,30]. Based on these data, we exclude CD133 in this study and focus only on CD166, CD44, and EpCAM.

The goal of this study is to identify and characterise the CSCs population in human NSCLC using CD166, CD44, and EpCAM as markers. We also conducted transcriptomic profiling of the isolated CSCs to determine how the transcriptome is involved in the signaling pathways specific to the CSCs of lung cancer.

Methods
Cell lines
The human lung cancer cell lines A549 (lung carcinoma) and H2170 (squamous cell carcinoma) and the normal primary human bronchial/tracheal epithelium (PHBEC) cell line were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA).

Cell culture
The cancer cell lines were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. Cells were incubated in a humidified incubator at 37°C and 5% CO₂. Cells were maintained in 75 cm² tissue culture flasks and harvested by 0.25% trypsin-EDTA treatment when they reached 80% confluency. Unless specified, all reagents were obtained from Gibco (Life Technologies, Foster City, CA, USA).

PHBECs were cultured in specific airway epithelial cell medium purchased from ATCC. The medium consists of airway epithelial cell basal medium (PCS-300-030) supplemented with the bronchial/tracheal epithelial growth kit (PCS-300-040), gentamicin-amphoterin B solution (PCS-
Isolated putative lung CSCs were cultured in low adherent 35 mm dishes under serum-free conditions and supplemented with 20 ng/ml of epidermal growth factor (EGF) (Life Technologies, Foster City, CA, USA) 10 ng/ml of basic fibroblast growth factor (bFGF) (Life Technologies), and B27 supplement (Life Technologies) for 21 days according to published protocols [15]. The experiment was conducted in three independent replicates for A549 and H2170 cells.

Adipogenic, chondrogenic, and osteogenic differentiation in vitro
The putative CSCs were induced to differentiate into different lineages using adipogenic, chondrogenic, and osteogenic differentiation media (PromoCell, Heidelberg Germany). Briefly, the putative CSCs were seeded in 24-well tissue culture plates until the cells reached 80–90% confluence (for adipogenic differentiation) or 100% confluence (for chondrogenic and osteogenic differentiation). The initial seeding number was 6 × 10^4 cells for adipogenic and chondrogenic differentiation and 1 × 10^5 cells for osteogenic differentiation. Once the cells reached the required confluency, two sets of triplicate wells were induced to differentiate by replacing the culture medium with the specific differentiation medium. The remaining wells containing the normal medium served as the control. The cells were incubated for 14 days (adipogenic differentiation) and 21 days (chondrogenic and osteogenic differentiation), and the medium was changed every 3 days.

Detection of differentiation in vitro
At the end of the incubation period, the cells were washed with PBS, fixed with 10% buffered formalin, and stained with a respective staining solution to detect adipocyte, chondrocyte, or osteocyte formation. Formation of adipocytes was detected by observing intracellular lipid vesicles stained red by 0.3% Oil Red O (Sigma-Aldrich, Munich, Germany). After the cells were fixed, they were incubated with 60% isopropanol at room temperature for 5 min. The isopropanol was carefully aspirated, and Oil Red O staining solution was added to cover the cells. The cells were incubated for 15 min, washed several times with distilled water, and counterstained with a Harris Hematoxylin solution for 1 min. Lastly, the cells were washed with distilled water and observed under the microscope.

Osteocyte formation was detected by staining calcium deposits with 2% Alizarin Red S (Sigma-Aldrich). The fixed cells were incubated with Alizarin Red S staining solution for 45 min at room temperature in the dark. The cells were washed four times with distilled water, and PBS was then added to each well. When observed under the microscope, extracellular calcium deposits were stained bright orange-red. Chondrogenic differentiation was detected by staining with Alcian blue staining solution (Sigma-Aldrich). The fixed cells were incubated with Alcian blue staining solution overnight at room temperature in the dark. The cells were washed four times with distilled water, and PBS then was added to each well. When observed under the microscope, the cartilages were stained an intense dark-blue, whereas other tissue was at most faintly bluish.
Expression of the stem cell transcription factors

The expression of stem cell transcription factors was detected using two step real time polymerase chain reaction (RT-PCR) analyses. Initially, total RNA was extracted from the sorted cells using a Qiagen AllPrep DNA/RNA Isolation Kit (Qiagen) according to the manufacturer’s instructions. Complementary DNA (cDNA) was synthesized from 1 μg of total RNA using the Transcriptor First Strand cDNA Synthesis Kit (Roche Applied Science, Mannheim, Germany). The random hexamer and anchorred-oligo (DT) primers were used. The RT-PCR reaction was prepared using SYBR Green 1 PCR reagents (KAPA Biosystems, Boston, USA), and the primer for the Sox2, Klf4, c-Myc, Nanog, Oct 3/4, and GAPDH genes from the Pluripotency Check PCR Primer Set (Clontech Laboratories Inc, Mountain View, USA) were used (Table 1). The RT-PCR reaction was performed using the ABI StepOnePlus™ PCR System (Applied Biosystems, Foster City, USA) under the following procedure: 95 °C for 4 min, 40 cycles of 95 °C for 15 sec, 60 °C for 30 sec, and 72 °C for 30 sec. Quantification was performed using the comparative Ct method. The normal stem cell was used as the control sample, and the GAPDH gene was used as the endogenous control.

Microarray analysis

Total RNA extraction and cDNA synthesis

Total RNA was extracted from up to 1 × 10^6 CD166+/CD44+ and CD166+/EpCAM+ PHBEC, A549, and H2170 cells using the Qiagen AllPrep DNA/RNA Isolation Kit (Qiagen) according to the manufacturer’s protocol. Briefly, the cells were lysed with lysis buffer and homogenized using the QIAshredder Homogenizer (Qiagen). Ethanol (70%) was then added to the homogenized cell lysates, and the cell lysates were transferred into the RNA spin column. Total RNA that bound to the spin column was eluted from the spin column using RNase free water. The concentration and purity of the extracted RNA were determined using a Nanodrop® ND1000 spectrophotometer, and the RNA integrity number (RIN) was determined using the Bioanalyzer 2100 (Agilent Technologies).

ST-cDNA amplification, purification, fragmentation, and labelling

Total RNA (1.5 μg) was amplified using the Applause™ WT-Amp ST System (Nugen Technologies, Inc., San Carlos, USA) following the manufacturer's protocol. The seven step amplification process produced ST-cDNA, which was further purified using the MinElute Reaction Cleanup Kit (Qiagen). The yield and purity of the purified ST-cDNA were measured using the Nanodrop® ND1000 spectrophotometer. The A260:A280 ratio must be > 1.8 and the concentration must be in the range of 2 to 2.5 μg for the ST-cDNA to be hybridised to the array. The purified ST-cDNA was then fragmented and labelled with biotin (Nugen Technologies).

Array hybridisation and scanning

Biotin-labelled fragmented ST-cDNA was hybridised to oligonucleotide probes on Affymetrix GeneChip® 1.0 ST arrays and then washed and stained using the GeneChip® Hybridisation Wash and Stain Kit. For each array, 2–2.5 μg of the fragmented biotin-ST-cDNA were hybridised to the arrays for 17 h at 45°C in a rotating

---

Table 1 List of primers used in RT-PCR for expression of stem cell transcription factors

| Genes | Forward primer | Reverse primer |
|-------|----------------|----------------|
| Sox2  | GGTACCTCTTTCTCCTCACCACCTCAG | TCAACATGTGCGGACAGGCGGAG |
| Klf4  | CACCATGACCTGCGCGTGGCTGAGGAAA | AAGCTGACTTGCGAAGACTTGACC |
| c-Myc | CAGAGGAGGAGACAGGAGCTGAGACGCGC | TTATTCACCGAGGATTCCGAGTTCG |
| Nanog | AGGGGTCCTGACTGAGATGGTGCCTG | CAAACACTGTTTCTCTGGCACCAGG |
| Oct 3/4 | CTGAGGCGCCGAGGCGGACGACGAG | CTGTAGGCGGCGGCTGAGGACCTT |
| GAPDH | CGCATGCTCTGTGAGTGC | CTGTGGTCTGAGGGCTCCTC |
| Sox2  | GGTACCTCTTTCTCCTCACCACCTCAG | TCAACATGTGCGGACAGGCGGAG |
hybridisation oven. The array was stained utilizing the FS450_0007 protocol of the Affymetrix Fluidics Station FS450. The arrays were scanned with an Affymetrix Scanner 3000, and data were obtained using the GeneChip® Operating Software. The microarray experiment was performed using three biological replicates for each sample.

Data processing and analysis
Microarray data analysis was performed using GeneSpring GX 7.3.1 software (Agilent Technologies). The CEL file of each array was normalized to the 50th percentile, and probes/genes with expressions less than the 50th percentile were excluded. To identify the significantly regulated genes of putative CSCs, statistical analysis was conducted by comparing the FC of putative CSCs to its normal counterparts (Table 2). The probes/genes then were filtered based on p-value and FC. Probes/genes with p-value < 0.05 and FC > 2.0 were assumed to be significantly regulated. The microarray raw data discussed in this paper were deposited in the NCBI GEO database (Accession number: GSE50627).

Microarray validation
The differentially expressed genes identified in the microarray analysis were validated by RT-PCR using Taqman® Gene expression assays (Applied Biosystems) in the ABI StepOnePlus™ Real-Time PCR machine. The PCR reactions included 1 μL of 20× Taqman® primer, 10 μL of 2× Taqman® Gene Expression master mix, 2 μL of cDNA template, and 7 μL of RNase free water. The RT-PCR thermal profile was obtained using the following procedure: 50°C for 2 min, 95°C for 20 sec, 40 cycles at 95°C for 15 sec and 60°C for 1 min. Table 3 lists the primer sequences used. The expression level of each target gene in the tested experimental condition (putative lung CSCs) was compared to that of the control condition (PHBEC), and the data was normalized to GAPDH gene expression.

Functional enrichment analysis
Functional enrichment analysis was performed using DAVID (http://david.abcc.ncifcrf.gov/) [31,32]. Significantly regulated genes (FC > 2; p < 0.05) from each group were submitted to DAVID. The analysis was started by clicking on “Start Analysis” on the header, and the gene list manager panel that appeared was used to perform the analysis step. First, the list of gene IDs was copied and pasted into box A, an appropriate gene identifier type (gene list or background) for the input gene ID was selected, and the submit button was pressed. If DAVID could not recognize more than 20% of the submitted gene ID, the submission was redirected to the DAVID Gene ID Conversion Tool. Once the list of genes was successfully submitted, the analysis of the list was performed using the available DAVID analysis tools. These tools include functional annotation tools, gene functional classification tools, and the gene name batch viewer.

Results
Expression of cancer stem cell markers in NSCLC cells
To identify the subpopulation of putative CSCs in cancer cell lines, we investigated the expression of three stem cell surface markers (CD166, CD44, and EpCAM) that previously were described as prominent CSCs markers in lung cancer. Expressions of CD166, CD44, and EpCAM varied among the cell lines. All surface markers except CD44 were expressed in all cell lines, but they exhibited different degrees of expression. CD166 was highly expressed in all cell lines: PHBEC (expressed in 38.7% of cells), A549 (72.9%), and H2170 (52.6%) (Figure 1). CD44 expression was detected only in the PHBEC cells (2.2%) and A549 cells (61.5%) (Figure 1). The expression of EpCAM differed among the cell lines, with the highest expression observed in the H2170 cells (33.8%) followed by the A549 cells (13.8%) and the PHBEC cells (4.9%) (Figure 1).

Co-expression of CD166 with CD44 and EpCAM to identify the subpopulation of NSCLC cells with stem cell-like properties
To identify a more stringent phenotype for the putative CSCs population, co-expression of two markers was investigated. Because the initial analysis using single marker expression showed that CD166 was the prominent marker in both cell lines, we evaluated co-expression of CD166 with CD44 and CD166 with EpCAM. In A549 cells, 62.5% of the cells expressed CD166/CD44 and 9.8% of the cells expressed CD166/EpCAM.

Table 2 Comparison groups in microarray data analysis conducted using gene spring software

| Group number | Comparison                                      |
|--------------|-------------------------------------------------|
| 1            | A549 CD166+/CD44+ vs. PHBEC CD166+/CD44+        |
| 2            | A549 CD166+/EpCAM+ vs. PHBEC CD166+/EpCAM+     |
| 4            | H2170 CD166+/EpCAM+ vs. PHBEC CD166+/EpCAM+    |

Table 3 List of genes and probe sequences used in the microarray validation assay

| Gene    | Primer sequence          |
|---------|--------------------------|
| CDH2    | ATCTCTGGTATCCTGTGCTGATGT |
| AKT3    | CAAATAAGCCCTTGGGAGAACCC  |
| EPHX1   | GAGGCTCTGAAAGAAAGTCTCCCT |
| ITGA3   | ACAAGACCACGGTGTTCTGTTGGA |
| THBS1   | TGAATACCTATTGAGATGCCTCTTA |
| LAMC2   | CTGGATCGACGAGCCTCTGCA    |
| GAPDH   | GACTCATGACCGACGTCCATGCCAT |
expressed CD166/EpCAM (Figure 2). In H2170 cells, only expression of CD166/EpCAM was observed in 3.1% of the cells (Figure 2). The double positive cells from the A549 and H2170 cell lines were sorted out and defined as putative lung CSCs. To validate the stemness characteristics of the putative lung CSCs, we also sorted out the double negative population (i.e., CD166^−/CD44^− and CD166^−/EpCAM^−) and called this population putative non-CSCs.

Putative lung CSCs exhibit differentiation potential
The characteristics of the putative CSCs and putative non-CSCs were assessed by their ability to differentiate into multilineage cells. The cells were induced to differentiate into adipogenic, osteogenic, and chondrogenic cells by culturing them in stem cell differentiation media. Putative CSCs of the A549 and H2170 cell lines were able to differentiate into adipogenic and osteogenic lineages (Figure 3). However, the putative non-CSCs lacked this characteristic (Figure 3). Neither putative CSCs nor putative non-CSCs of both cells lines could differentiate into chondrogenic cells (data are not shown).

Self-renewal ability of putative lung CSCs
Self-renewal capacity is one of the characteristics of stem cells. The results from the colony formation efficiency assay show that putative CSCs isolated from the A549 and H2170 cells were able to form colonies (Figure 4). However, putative non-CSCs isolated from both cell lines also had the ability to form colonies. We further validated the self-renewal characteristics of the cells by performing the sphere forming assay. After being cultured in serum-free medium supplemented with fibroblast growth factor (bFGF), epidermal growth factor (EGF), and B27 supplement, both putative lung CSCs and putative non-CSCs formed colonies. However, the colony size and the number of colonies formed differed: Putative lung CSCs formed more and larger colonies compared to putative non-CSCs (Figure 4). We concluded
that both putative CSCs and non-CSCs have self-renewal ability, but the capability is more prominent and higher in the putative lung CSCs.

**Putative lung CSCs exhibit stem cell gene expression**
The observation that the putative lung CSCs had the ability to differentiate into adipogenic and osteogenic cells led us to investigate whether these cells express stem cell transcription factors such as Sox2, Oct 3/4, Nanog, c-Myc, and Klf4. The expression of the genes was detected using the real-time polymerase chain reaction (RT-PCR) method, and the relative expression of the genes in putative CSCs was compared to the expression of the genes in normal stem cells (PHBEC). Detectable expression levels of these genes were found in putative CSCs of both cell lines (Figure 5). In A549 CD166+/CD44+ cells, Sox2 and Oct4 were up-regulated with FC values of 2.472 and 3.981 respectively. In A549 CD166+/EpCAM+ cells, expression of Oct3/4 (3.874) and c-Myc (2.619) was also detected. For H2170 CD166+EpCAM+ cells, expressions of Sox2 (FC = 4.753), Oct4 (17.484), Klf4 (3.017), and c-Myc (3.213) were up-regulated. The expression of Nanog was down-regulated in all putative CSCs.

**In vivo tumourigenicity properties of putative lung CSCs**
The ability of putative lung CSCs to develop tumours in vivo was investigated by subcutaneous transplantation of the cells into nude mice. The injected cells from parental, putative lung CSCs, and putative non-CSCs were able to initiate tumours in vivo, but the tumour sizes and tumour incidence differed between the treatments (Figure 6 and Table 4). Putative lung CSCs initiated the growth of larger tumours compared to parental cells and putative non-CSCs. In addition, putative lung CSCs formed tumours in all animals (n = 3), whereas putative non-CSCs formed tumours in two of the three injected...
animals (Table 4). The tumour growth rate for putative lung CSCs also was higher than those of parental and putative non-CSCs (Figure 6). Therefore, the in vivo tumourigenicity experiments demonstrated that the putative lung CSCs were more tumourigenic than the parental and putative non-CSCs.

Transcriptomic profiling of putative lung CSCs using microarray analysis

The mRNA expression profiles of putative lung CSCs were measured using Affymetrix Expression Console™ software (Affymetrix, Santa Clara, CA, USA), and the data were analysed using GeneSpring software version 12.5 (Agilent Technologies, Santa Clara, CA, USA). The intensity of each array was normalized to the 50th percentile of expression, and the significantly regulated genes were selected using independent $t$-test statistical analysis by comparing the data from the putative CSCs with those from normal lung stem cells. The genes that had a FC $> 2.0$ and a p-value $< 0.05$ were considered to be significantly regulated. The lists of significantly regulated genes are shown in the (Additional file 1: Table S1, Additional file 2: Table S2, and Additional file 3: Table S3) for each group. Table 5 summarises the numbers of significantly regulated genes for each putative CSC, and volcano plot analysis was used to visualise the significance and the magnitude of the significantly regulated genes (Figure 7). The number of significantly regulated genes ranged from 1229 to 1335, and the number of down-regulated genes was higher than that of up-regulated genes.

Validation of microarray data by RT-PCR

To verify the expression value of the microarray data, the original amplified RNA samples used for microarray analysis were validated for six genes using RT-PCR. Three of the selected genes were up-regulated and three were down-regulated. The expression values detected by both microarray and RT-PCR techniques were plotted as log2 FC (Figure 7). The Pearson correlation coefficient test showed that the expression values detected by both platforms were in agreement ($p < 0.05$) (Figure 7).
Functional enrichment analysis of differentially expressed genes in putative CSCs

To gain a better understanding of the functions of significantly regulated genes in lung CSCs, we conducted bioinformatics analysis using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) programme. We looked at the gene ontology (GO) terms for biological function and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways that are associated with the CSCs gene list. Up- and down-regulated genes in all three putative CSCs (A549 CD166⁺/CD44⁺, A549 CD166⁺/EpCAM⁺, and H2170 CD166⁺/EpCAM⁺) were found to be involved in several biological cancer processes, including angiogenesis, apoptosis, anti-apoptosis, induction of apoptosis, cell death, and cell migration. In addition, the three putative CSCs were found to share several development and stem cell related biological processes, such as ectoderm development, epidermis development, osteoblast differentiation, mesenchymal cell development, Wnt receptor signaling, lung development, regulation of the NF-kappa β cascade, and bone development (Figure 8).

A more informative analysis of functional annotation was achieved by studying the enrichment of differentially expressed genes in a particular pathway. The up-regulated genes were involved in cancer, ATP-binding cassette (ABC) transporter, Wnt signaling, drug metabolism, and NSCLC pathways (Table 6). The significant pathways for the down-regulated genes were the p53 signaling, apoptosis, Hedgehog signaling, ECM-receptor interaction, cancer, and SCLC pathways (Table 6).

Discussion

Because CSCs likely play an important role in maintaining cancer cell populations, targeting specific components of CSCs regulatory pathways could open up a new strategy for cancer treatment. Identification and isolation of CSCs from NSCLC cells is the initial step in identifying more specific CSCs markers in the NSCLC cell population. We found that CD166 was highly expressed in both normal and lung cancer cells, and we used the combinations of CD166/CD44 and CD166/EpCAM for further analysis.

The flow cytometry analysis revealed that the lung cancer cells consist of a heterogeneous population with different phenotypes (CD166⁺/CD44⁺, CD166⁺/CD44⁻, CD166⁻/CD44⁺, CD166⁻/CD44⁻, CD166⁺/EpCAM⁺, CD166⁺/EpCAM⁻, CD166⁻/EpCAM⁺, and CD166⁻/EpCAM⁻), which supports the initial hypothesis that the CSCs population is heterogeneous. We hypothesized that the double positive
cells (i.e., CD166⁺/CD44⁺ and CD166⁺/EpCAM⁺) are the putative lung CSCs in A549 and H2170 cells. The putative lung CSCs showed multilineage differentiation and self-renewal capability, which proved that they had the stem cell-like phenotype.

Results of previous studies support the use of CD166, CD44, and EpCAM as CSCs markers. The combination of CD166/CD44 was previously used to identify CSCs from colorectal cancer cell lines; CD166⁺/CD44⁺ cells were found to have higher clonogenicity and accelerated tumour development compared to CD166⁻/CD44⁻ cells, and the observation was cell dependent [33]. To date, there have been no reports of the combination of CD166/CD44 and CD166/EpCAM to identify lung CSCs, but co-expression of other CSCs markers to identify lung CSCs has been reported. For instance, Wang et al. combined CD44 and CD90 to identify lung CSCs [22]. They demonstrated that CD44⁺/CD90⁺ cells had therapy resistance and higher colony and spheroid forming potential when compared to CD44⁺/CD90⁻, CD44⁻/CD90⁺, and CD44⁻/CD90⁻ cells. Another study combined CD133 with CD44 to identify lung CSCs in A549 cells and found that CD133⁺/CD44⁺ cells had significant CSCs properties (i.e., continuous proliferative capacity and differential potential) [34].

In this study, the expression of surface markers differed between the tested cell lines, even though both are NSCLC cell lines. For example, 61.5% and 0.0% of A549 and H2170 cells, respectively, were CD44⁺. Other studies using the same A549 cells reported that 84.41% [35] and 0.0% [15] of A549 cells expressed CD44. Stuelten et al. also found inconsistent expression of CD44 in nine NSCLC cell lines, including A549 cells [35]. In addition, different expression levels of CD44 have been reported in other types of tumours, including colon, ovarian, and breast cancers [35]. We also found that CD166 and EpCAM expression differed between cell lines. We detected expression of CD166 in 72.9% and 52.56% of A549 and H2170 cells, respectively, whereas the values for EpCAM were 13.8% and 33.8%, respectively. The inconsistent expression profiles of CSCs markers among different studies could be related to individual cancer variations, different potency states, and functional
characteristics of the CSCs population. Thus, in the absence of a specific marker, the true percentage of CSCs in a tumour, particularly in long-established cancer cell lines, is controversial [36]. The variation in environmental and selective pressures experienced by cancer cells in vitro and in vivo might trigger or suppress different pathways that regulate CSCs functions, and it is not clear whether the CSCs profiles could vary with circumstances.

The abilities of the CD166+/CD44+ and CD166+/EpCAM+ A549 and H2170 cells to differentiate into adipogenic and osteogenic lineages and to express stem cell transcription factors showed their stem cell characteristics. Moreover, the increased tumorigenic ability of the putative lung CSCs as shown in in vivo study also indicated their cancer stem cells characteristic. Microarray analysis of putative lung CSCs was carried out to better understand the transcriptomic regulation of putative CSCs as compared to normal lung stem cells. Using microarray technology, transcription profiling was performed for

Table 4 In vivo tumourigenicity experiment of putative lung CSCs and non-putative CSCs

| Cell type          | Cell number injected | Tumour incidence | Tumour size (average) (cm) |
|--------------------|----------------------|------------------|---------------------------|
| A549 Parental      | 20,000               | 3 / 3            | 0.89                      |
| A549 CD166+/CD44+  | 20,000               | 3 / 3            | 1.00                      |
| A549 CD166+/CD44−  | 20,000               | 2 / 3            | 0.83                      |
| A549 CD166+/EpCAM+ | 20,000               | 3 / 3            | 1.18                      |
| A549 CD166−/EpCAM− | 20,000               | 2 / 3            | 0.70                      |
| H2170 Parental     | 20,000               | 3 / 3            | 1.28                      |
| H2170 CD166+/EpCAM+ | 20,000              | 3 / 3            | 1.39                      |
| H2170 CD166−/EpCAM− | 20,000              | 2 / 3            | 0.89                      |
| Control (media + matrigel) | 20,000       | 0 / 3            | 0                         |

Table 5 Number of significantly regulated genes (p < 0.05, fold change > 2.0) in putative CSCs compared to putative normal stem cells

| Groups                               | Number of genes |
|--------------------------------------|-----------------|
|                                      | Total Up-regulated | Down-regulated |
| A549 CD166+/CD44+ vs. PHBEC CD166+/CD44+ | 1229 598 (48.65%) | 631 (51.34%) |
| A549 CD166+/EpCAM+ vs. PHBEC CD166+/EpCAM+ | 1335 677 (50.71%) | 658 (49.28%) |
| H2170 CD166+/EpCAM+ vs. PHBEC CD166+/EpCAM+ | 1292 547 (42.33%) | 745 (57.66%) |
| Total                                | 3856 1822        | 2034            |
putative lung CSCs isolated from the two lung cancer cell lines. The composition of the up-regulated genes and their pathways showed that these genes play an important role in maintaining the stemness of the lung CSCs, whereas the dysregulated genes were involved in cellular repair. The GO term analysis showed consistent results, with the significantly regulated genes of putative CSCs being involved in stem cell related biological and development processes. These findings clearly illustrate that CSCs are present in lung cancer cells and that these isolated putative CSCs possess stem cell characteristics.

The significantly regulated genes identified in our study were involved in the Wnt and hedgehog pathways and were associated with the self-renewal process of normal stem cells [37]. The ability to self-renew is a special characteristic of stem cells, as it allows them to divide and maintain their stemness. Wnt and hedgehog signaling pathways have been reported to play an important role in carcinogenesis as well as in normal stem cell processes [4,38]. In addition, the over-expression of Wnt signaling molecules has been reported to be involved in drug resistance of A549 cells, and up-regulation of this signaling pathway was suggested to be one of the characteristics of CSCs [39]. Our microarray data showed that Wnt signaling was up-regulated only in putative CSCs of A549 cells; it was not detected in H2170 cells. This could explain the higher colony forming ability of A549 cells compared to H2170 cells.

**Figure 7 Microarray analysis and validation.** (A) Volcano plot of differentially expressed genes obtained from microarray analysis. The red coloured dots represent the differentially expressed genes (fold change > 2, p-value < 0.05). (B) Validation of the microarray data by RT-PCR for six genes in putative CSCs. Up-regulation of three genes (CDH2, AKT3, and EPHX1) and down-regulation of three genes (ITGA3, THBS1, and LAMC2) were observed in all cells. (C) Results of the correlation coefficient test between data from the microarray (log2) and RT-PCR (relative to GAPDH) assays for the genes subjected to the validation study. The X-axis shows the log transformed array data and the Y-axis shows the RT-PCR data for each sample.
The ECM interaction pathway is another pathway that showed a strong relationship with the putative CSCs transcriptome. Our data showed that this pathway was consistently conserved in putative CSCs regardless of cell type. The ECM is a non-cellular component of cells that consists of a complex mixture of structural and functional macromolecules, including proteins, glycoproteins, proteoglycans, and polysaccharides. The ECM plays an important role in tissue and organ morphogenesis and in the maintenance of cell and tissue structure and function [40,41]. In the present study, the genes involved in the ECM pathway, including laminin and integrins, were down-regulated (Table 7). It also has been suggested that the ECM is a non-cellular component of the adult stem cell niche [42,43]. The ECM plays a role in maintaining stem cell properties and in regulating stem cell differentiation [42,43]. The dysregulation of the ECM, which causes an imbalance between stem cell self-renewal and differentiation, might lead to the formation of CSCs. In addition, the dysregulation of ECM was associated with development and progression.
of tumours, as it promotes the tumour microenvironment [44]. An abnormal ECM also indirectly affects cancer cells by influencing the behavior of stromal cells, endothelial cells, immune cells, and fibroblasts, which are the main initial culprits that cause abnormal ECM production [44-46].

**Conclusions**

We successfully identified and characterised putative CSCs from NSCLC cells. The CSCs with the CD166+/CD44+ and CD166+/EpCAM+ phenotypes have the ability to differentiate into adipogenic and osteogenic lineages and possess self-renewal ability. The gene expression study revealed that the putative lung CSC transcriptome is significantly associated with stem cells and cancer biological processes, including angiogenesis, migration, pro-apoptosis and anti-apoptosis, osteoblast differentiation, mesenchymal cell differentiation, and mesenchyme development, and is involved in stem cell self-renewal pathways, Wnt and hedgehog signaling, and cancer-associated pathways. This study revealed that isolated putative lung CSCs exhibit the characteristics of multipotent stem cells, and their genetic composition might be valuable for future gene and stem cell therapy for lung cancer.

**Table 6 Common significant pathways associated with up-regulated and down-regulated genes of putative CSCs**

| Pathway ID | Pathways                              | Fold enrichment | A549 CD166+/CD44+ | A549 CD166+/EpCAM+ | H2170 CD166+/EpCAM+ |
|------------|---------------------------------------|-----------------|-------------------|-------------------|-------------------|
| **Up-regulated** |                                       |                 |                   |                   |                   |
| hsa09982   | Drug metabolism                       | 3.661           | –                 | –                 | –                 |
| hsa02010   | ABC transporters                      | 3.041           | –                 | –                 | –                 |
| hsa04010   | MAPK signalling pathway                | –               | 1.933             | 1.870             |                   |
| hsa04310   | Wnt signalling pathway                | 1.063           | 1.025             | –                 |                   |
| hsa04514   | Cell adhesion molecules (CAMs)         | 1.419           | –                 | 1.719             |                   |
| hsa04520   | Adherens junction                     | 1.390           | –                 | –                 | –                 |
| hsa05200   | Pathways in cancer                    | –               | 0.944             | 1.384             |                   |
| hsa05223   | Non-small cell lung cancer            | –               | 1.912             | 4.203             |                   |
| **Down-regulated** |                                   |                 |                   |                   |                   |
| hsa04115   | p53 signalling pathway                | 3.935           | 2.589             | 2.660             |                   |
| hsa04210   | Apoptosis                             | 1.957           | 2.783             | 2.079             |                   |
| hsa04340   | Hedgehog signalling pathway           | 1.737           | –                 | –                 |                   |
| hsa04512   | ECM-receptor interaction              | 3.765           | 3.668             | 3.589             |                   |
| hsa05200   | Pathways in cancer                    | 2.225           | 1.946             | 1.960             |                   |
| hsa05222   | Small cell lung cancer                | 2.027           | 2.096             | 2.392             |                   |

**Table 7 Genes involved in the ECM pathway**

| Gene symbol | Gene name       | Fold change | A549 CD166+/CD44+ | A549 CD166+/EpCAM+ | H2170 CD166+/EpCAM+ |
|-------------|-----------------|-------------|-------------------|-------------------|-------------------|
| ITGA2       | Integrin, alpha 2 | –6.453101  | –6.003461         | –5.65315          |
| ITGA3       | Integrin, alpha 3 | –3.122479  | –3.464945         | –6.222598         |
| ITGA5       | Integrin, alpha 5 | –3.526326  | –3.174653         | –5.131281         |
| ITGA6       | Integrin, alpha 6 | –3.517541  | –3.317876         | –4.317514         |
| ITGB4       | Integrin, beta 4  | –6.819779  | –5.698617         | –6.173566         |
| ITGB6       | Integrin, beta 6  | –22.19036  | –30.26098         | –3.902746         |
| ITGB8       | Integrin, beta 8  | –5.458705  | –4.551452         | –5.533338         |
| LAMA3       | Laminin, alpha 3 | –4.648527  | –4.327131         | –2.236711         |
| LAMB3       | Laminin, beta 3   | –8.490638  | –8.384007         | –4.292205         |
| LAMC2       | Laminin, gamma 2  | –42.03006  | –46.44047         | –11.52965         |
| TNC         | Tenascin C        | –8.586228  | –7.472796         | –6.891974         |
| THBS1       | Thrombospondin 1  | –6.843357  | –8.93955          | –29.22261         |
Additional files

Additional file 1: Table S1. List of significantly regulated genes of A549 CD166+/CD44+

Additional file 2: Table S2. List of significantly regulated genes of A549 CD166+/EpCAM+

Additional file 3: Table S3. List of significantly regulated genes of H2170 CD166+/EpCAM+

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
Conceived and designed the experiment: YB and ZN. Provided reagents and tools: YB, ZZ and YNM. Carried out experiment and analyzed the data: YB, ZN, LMM, BPJNM and FSK. Wrote the manuscript: YB and ZN. Contributed to the writing of the manuscript: YB, ZN, LMM, BPJNM and FSK. All authors read and approved the final manuscript.

Acknowledgements
This study was supported by grants from the Research University Grant scheme (1001/ CIPPT/811204) of Universiti Sains Malaysia.

Author details
1 Regenerative Medicine Cluster, Advanced Medical and Dental Institute (AMDI), Universiti Sains Malaysia, Bertam, 13200 Kepala Batas, Pulau Pinang, Malaysia.
2 Stem Cell Laboratory, Haematology Unit, Cancer Research Centre, Institute for Medical Research (IMR), Kuala Lumpur, Malaysia.

Received: 15 October 2014 Accepted: 12 February 2015

References
1. Mathers CD, Fat DM, Boerma J. The global burden of disease: 2004 update: World Health Organization, 2008
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49
3. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and stem cell-like cancers. Nature. 2001;414(6859):105–11
4. Zhou BBS, Zhang HY, Damelin M, Geles KG, Grindley JC, Dirks PB. Tumour- stem-like state. Proc Natl Acad Sci. 2011;108(19):7950–7
5. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100(7):3983–8
6. Li C, Heidt DG, Daletrea P, Burnt CF, Zhang L, Aday V, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67(13):1030–7.
7. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004;432 (7015):396–401.
8. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445(7123):106–10.
9. Ricci-Vitiani L, Lambardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445(7123):111-5.
10. Singh S, Hawkins C, Clarke I, Squire J, Bayani J, Hide T, et al. Identification of human brain tumor initiating cells. Nature. 2004;19:396–401.
11. Pece S, Tosoni D, Confalonieri S, Mazzafer G, Vecchi M, Ronzonni S, et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell. 2010;140(1):623–7.
12. Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kupershaw C, et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell. 2011;146(4):633–44.
13. Chaffer CL, Brueckman I, Scheel C, Kastel AJ, Wiggins PA, Rodrigues LO, et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci. 2011;108(19):7950–5.
14. Chaffer CL, Brueckmann I, Scheel C, Kastel AJ, Wiggins PA, Rodrigues LO, et al. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS One. 2010;5(11):e14062.
15. Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature. 2010;468(7325):292–3.
16. Malanchi I. Tumour cells coerce host tissue to cancer spread. BoneKyd Reports. 2013;371.
17. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou YJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704–15.
18. Bokolo AD, Razorovna OV, de van Rijn M, Swetter SM, Johnson DL, Ly DP, et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature. 2010;466(7302):133–7.
19. Eramo A, Lotti F, Sette G, Pilozi E, Biffoni M, Di Virgilio A, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008;15(3):504–14.
20. Zhang WC, Shyh-Chang N, Yang H, Rai A, Unashankar S, Ma S, et al. Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell. 2012;148(1–2):259–72.
21. Wang P, Gao Q, Suo Z, Munthe E, Solberg S, Ma L, et al. Identification and characterization of cells with cancer stem cell properties in human primary lung cancer lines. PLoS One. 2013;8(3):e57020.
22. Yin AH, Miraglia S, Zarjani ED, Almeida-Porada G, Ogawa M, Leary AG, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 1997;90(12):3002–12.
23. Meng X, Li M, Wang X, Wang Y, Ma D. Both CD133+ and CD133− subpopulations of A549 and H446 cells contain cancer-initiating cells. Cancer Sci. 2010;100(6):1040–6.
24. Howard BM, Bockxva JA. Stem cell marker CD133 expression predicts outcomes in glioma patients. Neurosurgery. 2005;62(6):INR.
25. Salnikov AV, Gladkich J, Moldenhauer G, Volin M, Mattrell J, Herr I. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int J Cancer J Int du Cancer. 2010;126(4):950–8.
26. Tirino V, Camerlingo R, Franco R, Malanga D, La Rocca A, Viglietto G, et al. The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. European J Cardio-Thoracic Surg Off J European Assoc Cardio-Thoracic Surgery. 2009;36(3):446–53.
27. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A. 2009;106(38):16281–6.
28. Wang J, Sakariassen PO, Tsinkalovsky O, Immervoll H, Boe SQ, Svendsen A, et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer J Int du Cancer. 2008;123(4):761–8.
29. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133−metastatic colon cancer cells initiate tumors. J Clin Invest. 2008;118(6):2111.
30. Dennis JR, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 2003;4:59.
31. da Huang W, Sherman BT, Tan Q, Collins. JR, Alvord WG, Roayaie J, et al. The DAVID gene functional classification tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol. 2007(8):R183.
32. Munaro MG, Mele V, Daster S, Han J, Heberer M, Cesare Spagnoli G, et al. CD133+, CD166 + CD44+, and CD44 + CD44+ phenotypes fail to reliably identify cell populations with cancer stem cell functional features in established human colorectal cancer cell lines. Stem Cells Transl Med. 2012;1(8):592–603.
33. Zhang H, Lin X, Hua P, Wang M, Ao X, Xiong L, et al. The study of the tumor stem cell properties of CD133+ CD44+ cells in the human lung adenocarcinoma cell line A549. Cell Mol Biol (Noisy-le-Grand, France). 2010;56:OL1350.
34. Stuelten CH, Mertins SD, Busch JI, Gowens M, Scudiero DA, Burkett MW, et al. Complex display of putative tumor stem cell markers in the NCIC60 tumor cell line panel. Stem Cells. 2010;28(6):649–60.
35. Alexander CM, Puchalski J, Klos KS, Badgers N, Allies L, Kim CF, et al. Separating stem cells by flow cytometry: reducing variability for solid tissues. Cell Stem Cell. 2009;5(6):579–83.
36. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumors: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8(10):755–68.
38. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005;434(7035):843–50.
39. Teng Y, Wang X, Wang Y, Ma D. Wnt/beta-catenin signaling regulates cancer stem cells in lung cancer A549 cells. Biochem Biophys Res Commun. 2010;392(3):373–9.
40. Whittaker CA, Bergeron KF, Whittle J, Brandhorst BP, Burke RD, Hynes RO. The echinoderm adhesome. Dev Biol. 2006;300(1):252–66.
41. Ozbek S, Balasubramanian PG, Chiquet-Ehrismann R, Tucker RP, Adams JC. The evolution of extracellular matrix. Mol Biol Cell. 2010;21(24):4300–5.
42. Raymond K, Deugnier MA, Faraldo MM, Glukhova MA. Adhesion within the stem cell niches. Curr Opin Cell Biol. 2009;21(5):623–9.
43. Shen Q, Wang Y, Kocovay E, Lin C, Chuang SM, Goderie SK, et al. Adult SVZ stem cells lie in a vascular niche: a quantitative analysis of niche cell-cell interactions. Cell Stem Cell. 2008;3(3):289–300.
44. Bhowmick NA, Nelson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004;432(7015):332–7.
45. Quante M, Tu SP, Tomita H, Gonda T, Wang SS, Takashi S, et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell. 2011;19(2):257–72.
46. Orimo A, Gupta PB, Sgroi DC, Arentzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121(3):335–48.